The Department of Health and Human Services announced coordinated actions across its component agencies to transition federal biomedical research away from animal testing and toward human-based methods on Sept. 22.
The initiative, directed by HHS Secretary Robert F. Kennedy Jr., encompasses simultaneous policy releases from the National Institutes of Health and the Food and Drug Administration — a rare multi-agency rollout signaling a formal department-wide shift in how the federal government funds and regulates scientific research.
The actions span drug development, product safety testing and federally funded scientific research infrastructure, according to HHS. The department said the coordinated approach is designed to accelerate the adoption of human-based alternatives across the entire biomedical research enterprise.
The announcement represents a significant departure from decades of federal reliance on animal models, which have formed the foundation of pre-market drug testing and publicly funded biomedical research since the modern regulatory framework was established.
Kennedy has long advocated for animal welfare and alternative research methods. The policy shift aligns with positions he articulated before and during his confirmation process as HHS secretary.
The scope of the initiative touches virtually every corner of the federal health research apparatus. NIH, the world’s largest public funder of biomedical research, announced parallel investments in human-based research technologies, while FDA released regulatory updates affecting how pharmaceutical and biotech companies may satisfy testing requirements.
Industry groups have expressed mixed views on the transition. Supporters argue that human-based models — including organ-on-a-chip technologies, advanced computer modeling and human tissue studies — can produce more accurate results for human patients. Critics have cautioned that moving too quickly away from established animal models could introduce safety risks into the drug development pipeline.
The coordinated rollout affects researchers, pharmaceutical companies and regulatory scientists across the country and could reshape federal research grant priorities for years to come.
HHS said additional implementation details would follow as individual agencies develop timelines for the transition.